Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

JAK Inhibition Mediates Clonal Selection of RAS Pathway Mutations in Myeloproliferative Neoplasms

Blood (2022) 140 (Supplement 1): 795–796.

https://doi.org/10.1182/blood-2022-167719

Published: 2022

Journal Articles

p53 activation during ribosome biogenesis regulates normal erythroid differentiation

Blood (2021) 137 (1): 89–102.

https://doi.org/10.1182/blood.2019003439

Published: 2021

Includes: Supplemental data

Journal Articles

BCL-2 Inhibitor Venetoclax (ABT-199) and MEK Inhibitor GDC-0973 Synergise to Target AML Progenitors and Overcome Drug Resistance with the Use of PET Scanning in a Mouse Model of HR-MDS to Monitor Response to Treatment

Rose Ann Padua, PhD, Laure Sarda-Mantel, MD PhD, Mathieu Chiquet, BSc, Claire Kappel, BSc, Patricia Krief, PhD, Niclas Setterblad, PhD, Fortune Hontonnou, BSc, Benoit Hosten, PhD, Nicolas Vignal, BSc, Fabien Zassadowski, PhD, Bruno Cassinat, PharmD, PhD, Panhong Gou, BSc, Stephane Giraudier, MD PhD, Marina Y. Konopleva, MD PhD, Michael Andreeff, MD PhD, Marika PLA, PhD, Lionel Ades, MD PhD, Pierre Fenaux, MD PhD, Christine Chomienne, MD PhD

Blood (2018) 132 (Supplement 1): 5497.

https://doi.org/10.1182/blood-2018-99-114212

Published: 2018

Journal Articles

BCL-2 Inhibition with ABT-199 Shows Efficacy in AML Cell Lines with Synergistic Effects upon Addition of the MEK Inhibitor GDC-0973 and Prolongs Survival in an NAS/BCL-2-Mediated Mouse Model of AML Post-MDS

Rose Ann Padua, PhD, Mathieu Chiquet, BSc, Qi Zhang, PhD MD, Claire Kappel, Patricia Krief, PhD, Niclas Setterblad, PhD, Dr Omidvar, BSc, MSc, PhD, Marina Konopleva, MD PhD, Michael Andreeff, MD PhD, Marika PLA, PhD, Lionel Ades, MD PhD, Pierre Fenaux, MD PhD, Christine Chomienne, MD PhD

Blood (2017) 130 (Supplement 1): 2613.

https://doi.org/10.1182/blood.V130.Suppl_1.2613.2613

Published: 2017

Journal Articles

Efficacy of ABT-737, a BCL-2 Inhibitor, in an NRAS/BCL2 Mouse Model of High Risk Myelodysplasia (HR-MDS) By Targeting Pathways Identified By Gene Expression Profiling

Blood (2014) 124 (21): 3249.

https://doi.org/10.1182/blood.V124.21.3249.3249

Published: 2014

Journal Articles

Proteasome Activity Is Dispensable for the Degradation of PML-RARα: Efficacy of Bortezomib Along with Arsenic Trioxide in the Treatment of Arsenic Sensitive and Resistant Acute Promyelocytic Leukemia

Saravanan Ganesan, MSc, Ansu Abu Alex, MSc, Ezhilarasi Chendamarai, PhD, Nithya Balasundaram, MSc, Hamenth Kumar Palani, MSc, Sachin David, MSc, Jayandharan G Rao, PhD, Aby Abraham, MD, Auro Viswabandya, MD, Biju George, MD, Alok Srivastava, MD, Poonkuzhali Balasubramanian, PhD, Rose Ann Padua, PhD, Christine Chomienne, MD PhD, Vikram Mathews, MD

Blood (2014) 124 (21): 3741.

https://doi.org/10.1182/blood.V124.21.3741.3741

Published: 2014

Journal Articles

pVAX14 DNA, An Immunoadjuvant, Extends Life-Span As Add-On Treatment To Azacitidine (AZA) In A Mouse Model Of High Risk Myelodysplastic Syndrome (HR-MDS)

Gorombei Petra, Le Pogam Carole, MSc, Patricia Krief, PhD, Satyananda Patel, PhD, Guerenne Laura, West Robert, PhD, Pla Marika, PhD, Fenaux Pierre, Chomienne Christine, Rose Ann Padua, PhD

Blood (2013) 122 (21): 1514.

https://doi.org/10.1182/blood.V122.21.1514.1514

Published: 2013

Journal Articles

NK Cell Mediated Cytotoxicity Against Malignant Promyelocytes Enhanced By Arsenic Trioxide: Potential Clinical Relevance

Ansu Abu Alex, MSc, Hamenth Kumar P, MSc, Saravanan Ganesan, MSc, Nithya Balasundaram, MSc, Kavitha M Lakshmi, MSc, Biju George, MD, Aby Abraham, MD, Auro Viswabandya, MD, Alok Srivastava, MD, Rose Ann Padua, PhD, Christine Chomienne, MD, PhD, Poonkuzhali Balasubramanian, Ph.D, Vikram Mathews, MD

Blood (2013) 122 (21): 1455.

https://doi.org/10.1182/blood.V122.21.1455.1455

Published: 2013

Journal Articles

pVAX14 DNA, a Non-Specific DNA Vaccine, Improves Survival In An Acute Promyelocytic Leukemia (APL) Mouse Model Treated With All-Trans Retinoic Acid (ATRA) and Arsenic Trioxide (ATO) and Targets Leukemia Initiating Cells (LICs)

Satyananda Patel, PhD, Laura Guerenne, Carole Le Pogam, Petra Gorombei, Patricia Krief, PhD, Marie-Helene Schlageter, Robert West, Vikram Mathews, MD, Marika Pla, PhD, Pierre Fenaux, MD, PhD, Christine Chomienne, MD, PhD, Rose Ann Padua, PhD

Blood (2013) 122 (21): 235.

https://doi.org/10.1182/blood.V122.21.235.235

Published: 2013

Journal Articles

BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells

Blood (2013) 122 (16): 2864–2876.

https://doi.org/10.1182/blood-2012-07-445635

Published: 2013

Includes: Supplemental data

Journal Articles

Tracking the Extramedullary PML-RARα-Positive Cell Reservoirs in a Preclinical Model of APL: Biomarker of Long-Term Drug Efficacy

Katerina Pokorna, PhD, Carole Le Pogam, BSc, Martine Chopin, Bruno Cassinat, PharmD, PhD, Pierre Fenaux, MD, PhD, Christine Chomienne, MD, PhD, Rose Ann Padua, PhD, Marika Pla, PhD

Blood (2012) 120 (21): 1510.

https://doi.org/10.1182/blood.V120.21.1510.1510

Published: 2012

Journal Articles

NRAS:BCL-2 Complex Localization Determines Anti-Apoptotic Features Associated with Progressive Disease in Myelodysplastic Syndromes (MDS)

Blood (2012) 120 (21): 3835.

https://doi.org/10.1182/blood.V120.21.3835.3835

Published: 2012

Journal Articles

BCL-2 Inhibition with ABT-737 Prolongs Survival in an NRAS/BCL2-Mediated MOUSE MODEL of Myelodyspastic Syndrome (MDS) Progressing to ACUTE Myelogenous Leukemia (AML) by Targeting Leukemia Initiating CELLS

Petra Gorombei, MSc, Beurlet Stephanie, DMV, PhD, Nader Omidvar, PhD, Krief Patricia, PhD, Le Pogam Carole, MSc, Pierre de la Grange, PhD, Leboeuf Christophe, MD, PhD, Anne Janin, MD, PhD, Noguera Maria-Elena, MD, Marina Konopleva, MD, PhD, Michael Andreeff, MD, PhD, Pla Marika, PhD, West Robert, PhD, Pierre Fenaux, MD, PhD, Christine Chomienne, MD, PhD, Rose Ann Padua, PhD

Blood (2012) 120 (21): 678.

https://doi.org/10.1182/blood.V120.21.678.678

Published: 2012

Journal Articles

Lithium Treatment Potentiates Both in Vitro and in Vivo Retinoic Acid Efficacy in APL.

Fabien Zassadowski, PhD, Katka Pokorna, PhD, Nicolas Ferre, Laura Llopis, PharmD, Oussama Chourbagi, PhD, Joel Poupon, PharmD, Martine Chopin, Pierre Fenaux, MD, PhD, Rose Ann Padua, PhD, Marika Pla, PhD, Christine Chomienne, MD, PhD, Bruno Cassinat, PharmD, PhD

Blood (2012) 120 (21): 2614.

https://doi.org/10.1182/blood.V120.21.2614.2614

Published: 2012

Journal Articles

ABT-737 Targets Leukemic Stem Cells In Mouse Models of Mutant NRASD12/hBCL-2- Mediated Acute Myeloid Leukemia Progression with Increased Survival

Blood (2010) 116 (21): 3308.

https://doi.org/10.1182/blood.V116.21.3308.3308

Published: 2010

Journal Articles

Mutant BCL2 Co-Operates with CBFβ/PEBP2β-MYH11 to Promote Expansion of Leukemia Initiating Cells with a Predominantly Pro-Apoptotic Mechanism Via Recruitment of Ras-GTP In a Mouse Model of Progressive Acute Myeloid Leukemia.

Nader Omidvar, PhD, Carole Le Pogam, BSc, Stephanie Beurlet, DMV, Maria-Elena Noguera, MD, Ann Janin, MD, PhD, Scott C. Kogan, MD, Irving L. Weissman, MD, Marika Pla, PhD, Christine Chomienne, MD, PhD, Rose Ann Padua, PhD

Blood (2010) 116 (21): 1050.

https://doi.org/10.1182/blood.V116.21.1050.1050

Published: 2010

Journal Articles

DNA and All-Trans Retinoic Acid as Immunotherapy or Add-on Adjuvants to 5-Azacytidine In Myelodysplastic Syndromes

Carole Le Pogam, BSc, Patricia Krief, PhD, Stéphanie Beurlet, DMV, Murielle Reboul, Robert West, PhD, Marika Pla, PhD, Dominique Charron, MD, PhD, Pierre Fenaux, MD, PhD, Christine Chomienne, MD, PhD, Rose Ann Padua, PhD

Blood (2010) 116 (21): 2938.

https://doi.org/10.1182/blood.V116.21.2938.2938

Published: 2010

Journal Articles

DNA vaccination with all- trans retinoic acid treatment induces long-term survival and elicits specific immune responses requiring CD4 + and CD8 + T-cell activation in an acute promyelocytic leukemia mouse model

Kouichi Furugaki, Katerina Pokorna, Carole Le Pogam, Masayuki Aoki, Murielle Reboul, Véronique Bajzik, Patricia Krief, Anne Janin, Marie-Elena Noguera, Robert West, Dominique Charron, Christine Chomienne, Marika Pla, Hélène Moins-Teisserenc, Rose Ann Padua

Blood (2010) 115 (3): 653–656.

https://doi.org/10.1182/blood-2007-08-109009

Published: 2010

Includes: Supplemental data

Journal Articles

ABT-737 Targets Intrinsic Apoptosis during Cooperation of BCL-2 and Oncogenic NRAS in An in Vivo Progression Model of Myelodysplasia/Acute Myeloid Leukaemia

Nader Omidvar, Stephanie Beurlet, Carole Le Pogam, Anne Janin, Christophe Leboeuf, Annie Soulie, Niclas Setterblad, Maria-Elena Noguera, Laure Sarda-Mantel, Pascal Merlet, Marika Pla, Scott C. Kogan, MD, Irving L Weissman, Marina Konopleva, William Bormann, Michael Andreeff, Christine Chomienne, Rose Ann Padua

Blood (2008) 112 (11): 848.

https://doi.org/10.1182/blood.V112.11.848.848

Published: 2008

Journal Articles

DNA Vaccination and All-Trans Retinoic Acid Treatment-Induced Long Term Survival Requires CD4+ and CD8+ T-Cell Activation in An APL Mouse Model.

Rose Ann Padua, PhD, Kouichi Furugaki, MD, PhD, Helene Moins-Teisserenc, MD, PhD, Katerina Pokorna, Carole Le Pogam, Murielle Reboul, Masayuki Aoki, PhD, Veronique Bajzik, Patricia Krief, PhD, Anne Janin, MD, PhD, Maria-Elena Noguera, MD, Robert West, PhD, Marie-Helene Schlageter, PhD, Dominique Charron, MD, PhD, Marika Pla, PhD, Christine Chomienne, MD, PhD

Blood (2008) 112 (11): 962.

https://doi.org/10.1182/blood.V112.11.962.962

Published: 2008

NARROW

JAK Inhibition Mediates Clonal Selection of RAS Pathway Mutations in Myeloproliferative Neoplasms

p53 activation during ribosome biogenesis regulates normal erythroid differentiation

BCL-2 Inhibitor Venetoclax (ABT-199) and MEK Inhibitor GDC-0973 Synergise to Target AML Progenitors and Overcome Drug Resistance with the Use of PET Scanning in a Mouse Model of HR-MDS to Monitor Response to Treatment

BCL-2 Inhibition with ABT-199 Shows Efficacy in AML Cell Lines with Synergistic Effects upon Addition of the MEK Inhibitor GDC-0973 and Prolongs Survival in an NAS/BCL-2-Mediated Mouse Model of AML Post-MDS

Efficacy of ABT-737, a BCL-2 Inhibitor, in an NRAS/BCL2 Mouse Model of High Risk Myelodysplasia (HR-MDS) By Targeting Pathways Identified By Gene Expression Profiling

Proteasome Activity Is Dispensable for the Degradation of PML-RARα: Efficacy of Bortezomib Along with Arsenic Trioxide in the Treatment of Arsenic Sensitive and Resistant Acute Promyelocytic Leukemia

pVAX14 DNA, An Immunoadjuvant, Extends Life-Span As Add-On Treatment To Azacitidine (AZA) In A Mouse Model Of High Risk Myelodysplastic Syndrome (HR-MDS)

NK Cell Mediated Cytotoxicity Against Malignant Promyelocytes Enhanced By Arsenic Trioxide: Potential Clinical Relevance

pVAX14 DNA, a Non-Specific DNA Vaccine, Improves Survival In An Acute Promyelocytic Leukemia (APL) Mouse Model Treated With All-Trans Retinoic Acid (ATRA) and Arsenic Trioxide (ATO) and Targets Leukemia Initiating Cells (LICs)

BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells

Tracking the Extramedullary PML-RARα-Positive Cell Reservoirs in a Preclinical Model of APL: Biomarker of Long-Term Drug Efficacy

NRAS:BCL-2 Complex Localization Determines Anti-Apoptotic Features Associated with Progressive Disease in Myelodysplastic Syndromes (MDS)

BCL-2 Inhibition with ABT-737 Prolongs Survival in an NRAS/BCL2-Mediated MOUSE MODEL of Myelodyspastic Syndrome (MDS) Progressing to ACUTE Myelogenous Leukemia (AML) by Targeting Leukemia Initiating CELLS

Lithium Treatment Potentiates Both in Vitro and in Vivo Retinoic Acid Efficacy in APL.

ABT-737 Targets Leukemic Stem Cells In Mouse Models of Mutant NRASD12/hBCL-2- Mediated Acute Myeloid Leukemia Progression with Increased Survival

Mutant BCL2 Co-Operates with CBFβ/PEBP2β-MYH11 to Promote Expansion of Leukemia Initiating Cells with a Predominantly Pro-Apoptotic Mechanism Via Recruitment of Ras-GTP In a Mouse Model of Progressive Acute Myeloid Leukemia.

DNA and All-Trans Retinoic Acid as Immunotherapy or Add-on Adjuvants to 5-Azacytidine In Myelodysplastic Syndromes

DNA vaccination with all- trans retinoic acid treatment induces long-term survival and elicits specific immune responses requiring CD4 + and CD8 + T-cell activation in an acute promyelocytic leukemia mouse model

ABT-737 Targets Intrinsic Apoptosis during Cooperation of BCL-2 and Oncogenic NRAS in An in Vivo Progression Model of Myelodysplasia/Acute Myeloid Leukaemia

DNA Vaccination and All-Trans Retinoic Acid Treatment-Induced Long Term Survival Requires CD4+ and CD8+ T-Cell Activation in An APL Mouse Model.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only